COMPANY

Protego Biopharma

HQ: San Diego, CA source · protegobio.com ↗ · West Coast

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: PROT-001

Timeline

Record	Title	Phase	Status	Start	Primary completion
NCT06981299	A Phase 1 Study of PROT-001.	1	Completed	May 29, 2025	Dec 23, 2025 (actual)

Annual award amounts. Total $3.7M.

Nov 24, 2022 NIH award 5U44NS114151-03 FY2023: $700,619 awarded for that fiscal year; activity U44 (SBIR); PI JIANG, XIN; recipient as written: PROTEGO BIOPHARMA, INC., SAN DIEGO, CA. Analytical Validation of Non-native Transthyr source ↗
Apr 29, 2021 NIH award 4U44NS114151-02 FY2021: $1,368,143 awarded for that fiscal year; activity U44 (SBIR); PI JIANG, XIN; recipient as written: PROTEGO BIOPHARMA, INC., SAN DIEGO, CA. Analytical Validation of Non-native Transth source ↗
Aug 4, 2020 NIH award 5R43NS108814-02 FY2020: $210,042 awarded for that fiscal year; activity R43 (SBIR); PI LABAUDINIERE, RICHARD; recipient as written: PROTEGO BIOPHARMA, INC., SAN DIEGO, CA. Development of An Oral, Brain/Eye source ↗
Apr 7, 2020 NIH award 1U44NS114151-01 FY2020: $700,000 awarded for that fiscal year; activity U44 (SBIR); PI JIANG, XIN; recipient as written: PROTEGO BIOPHARMA, INC., SAN DIEGO, CA. Analytical Validation of Non-native Transthyr source ↗
Sep 16, 2019 NIH award 1R43NS108814-01A1 FY2019: $419,185 awarded for that fiscal year; activity R43 (SBIR); PI LABAUDINIERE, RICHARD; recipient as written: PROTEGO BIOPHARMA, INC., SAN DIEGO, CA. Development of An Oral, Brain/E source ↗
Feb 27, 2018 NIH award 1R43TR002436-01 FY2018: $325,000 awarded for that fiscal year; activity R43 (SBIR); PI JIANG, XIN; recipient as written: PROTEGO BIOPHARMA, INC., SAN DIEGO, CA. Development of an early diagnostic and biomar source ↗